Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance.

Humans Bile Duct Neoplasms / therapy Cholangiocarcinoma / etiology Consensus Bile Ducts, Intrahepatic / metabolism

Journal

Nature reviews. Gastroenterology & hepatology

ISSN: 1759-5053

Titre abrégé: Nat Rev Gastroenterol Hepatol

Pays: England

ID NLM: 101500079

Informations de publication

Date de publication:
07 2023

Historique:

accepted: 20 12 2022

medline: 29 6 2023

pubmed: 10 2 2023

entrez: 9 2 2023

Statut: ppublish

Résumé

Cholangiocarcinoma (CCA) is a rare malignancy that develops at any point along the biliary tree. CCA has a poor prognosis, its clinical management remains challenging, and effective treatments are lacking. Therefore, preclinical research is of pivotal importance and necessary to acquire a deeper understanding of CCA and improve therapeutic outcomes. Preclinical research involves developing and managing complementary experimental models, from in vitro assays using primary cells or cell lines cultured in 2D or 3D to in vivo models with engrafted material, chemically induced CCA or genetically engineered models. All are valuable tools with well-defined advantages and limitations. The choice of a preclinical model is guided by the question(s) to be addressed; ideally, results should be recapitulated in independent approaches. In this Consensus Statement, a task force of 45 experts in CCA molecular and cellular biology and clinicians, including pathologists, from ten countries provides recommendations on the minimal criteria for preclinical models to provide a uniform approach. These recommendations are based on two rounds of questionnaires completed by 35 (first round) and 45 (second round) experts to reach a consensus with 13 statements. An agreement was defined when at least 90% of the participants voting anonymously agreed with a statement. The ultimate goal was to transfer basic laboratory research to the clinics through increased disease understanding and to develop clinical biomarkers and innovative therapies for patients with CCA.

Identifiants

DOI: 10.1038/s41575-022-00739-y PMID: 36755084

pubmed: 36755084

doi: 10.1038/s41575-022-00739-y

pii: 10.1038/s41575-022-00739-y

doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

462-480

Investigateurs

Lewis Roberts (L)

Alexander Scheiter (A)

Florin M Selaru (FM)

Katja Evert (K)

Kirsten Utpatel (K)

Laura Broutier (L)

Massimiliano Cadamuro (M)

Meritxell Huch (M)

Robert Goldin (R)

Sergio A Gradilone (SA)

Yoshimasa Saito (Y)

Informations de copyright

Références

Marin, J. J. G., Herraez, E., Lozano, E., Macias, R. I. R. & Briz, O. Models for understanding resistance to chemotherapy in liver cancer. Cancers 11, 1677 (2019).

pubmed: 31671735 pmcid: 6896032 doi: 10.3390/cancers11111677

Banales, J. M. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 17, 557–588 (2020).

pubmed: 32606456 pmcid: 7447603 doi: 10.1038/s41575-020-0310-z

Zach, S., Birgin, E. & Rückert, F. Primary cholangiocellular carcinoma cell lines. J. Stem Cell Res. Transplant. 2, 1013 (2015).

Martinez-Becerra, P. et al. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. Mol. Pharm. 9, 1693–1704 (2012).

pubmed: 22524153 doi: 10.1021/mp300028a

Raggi, C. et al. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. J. Hepatol. 66, 102–115 (2017).

pubmed: 27593106 doi: 10.1016/j.jhep.2016.08.012

Marsee, A. et al. Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. Cell Stem Cell 28, 816–832 (2021).

pubmed: 33961769 doi: 10.1016/j.stem.2021.04.005

Broutier, L. et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat. Med. 23, 1424–1435 (2017).

pubmed: 29131160 pmcid: 5722201 doi: 10.1038/nm.4438

Weiswald, L. B., Bellet, D. & Dangles-Marie, V. Spherical cancer models in tumor biology. Neoplasia 17, 1–15 (2015).

pubmed: 25622895 pmcid: 4309685 doi: 10.1016/j.neo.2014.12.004

Nuciforo, S. et al. Organoid models of human liver cancers derived from tumor needle biopsies. Cell Rep. 24, 1363–1376 (2018).

pubmed: 30067989 pmcid: 6088153 doi: 10.1016/j.celrep.2018.07.001

Loeuillard, E., Fischbach, S. R., Gores, G. J. & Rizvi, S. Animal models of cholangiocarcinoma. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 982–992 (2019).

pubmed: 29627364 doi: 10.1016/j.bbadis.2018.03.026

Leiting, J. L. et al. Biliary tract cancer patient-derived xenografts: surgeon impact on individualized medicine. JHEP Rep. 2, 100068 (2020).

pubmed: 32181445 pmcid: 7066236 doi: 10.1016/j.jhepr.2020.100068

Saborowski, A. et al. Murine liver organoids as a genetically flexible system to study liver cancer in vivo and in vitro. Hepatol. Commun. 3, 423–436 (2019).

pubmed: 30859153 pmcid: 6396372 doi: 10.1002/hep4.1312

Wang, J. et al. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis. J. Hepatol. 71, 742–752 (2019).

pubmed: 31195063 pmcid: 6773530 doi: 10.1016/j.jhep.2019.05.027

Primrose, J. N. et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 20, 663–673 (2019).

pubmed: 30922733 doi: 10.1016/S1470-2045(18)30915-X

Jusakul, A. et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 7, 1116–1135 (2017).

pubmed: 28667006 pmcid: 5628134 doi: 10.1158/2159-8290.CD-17-0368

Abou-Alfa, G. K. et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 21, 796–807 (2020).

pubmed: 32416072 pmcid: 7523268 doi: 10.1016/S1470-2045(20)30157-1

Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671–684 (2020).

pubmed: 32203698 pmcid: 8461541 doi: 10.1016/S1470-2045(20)30109-1

Roskoski, R. Jr Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update. Pharmacol. Res. 175, 106037 (2022).

pubmed: 34921994 doi: 10.1016/j.phrs.2021.106037

Izquierdo-Sanchez, L. et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA registry. J. Hepatol. 76, 1109–1121 (2022).

pubmed: 35167909 doi: 10.1016/j.jhep.2021.12.010

WHO Classification of Tumours Editorial Board. Digestive System Tumours: WHO Classification of Tumours 5th edn Vol. 1 (WHO, 2019).

Goyal, L. et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 7, 252–263 (2017).

pubmed: 28034880 doi: 10.1158/2159-8290.CD-16-1000

Lowery, M. A. et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol. Hepatol. 4, 711–720 (2019).

pubmed: 31300360 pmcid: 7934945 doi: 10.1016/S2468-1253(19)30189-X

Saborowski, A., Vogel, A. & Segatto, O. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma. Trends Cancer 8, 83–86 (2022).

pubmed: 34840108 doi: 10.1016/j.trecan.2021.11.001

Wu, M. J., Shi, L., Merritt, J., Zhu, A. X. & Bardeesy, N. Biology of IDH mutant cholangiocarcinoma. Hepatology 75, 1322–1337 (2022).

pubmed: 35226770 doi: 10.1002/hep.32424

Brierley, J. D., Gospodarowicz, M. K. & Wittekind, C. TNM Classification of Malignant Tumours 8th edn (Union for International Cancer Control, 2017).

Amin, M. B. et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J. Clin. 67, 93–99 (2017).

pubmed: 28094848 doi: 10.3322/caac.21388

Guglielmi, A. et al. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J. Surg. 33, 1247–1254 (2009).

pubmed: 19294467 doi: 10.1007/s00268-009-9970-0

Kendall, T. et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 39 (Suppl. 1), 7–18 (2019).

pubmed: 30882996 doi: 10.1111/liv.14093

Zen, Y., Quaglia, A., Heaton, N., Rela, M. & Portmann, B. Two distinct pathways of carcinogenesis in primary sclerosing cholangitis. Histopathology 59, 1100–1110 (2011).

pubmed: 22175890 doi: 10.1111/j.1365-2559.2011.04048.x

Radwan, N. A. & Ahmed, N. S. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Diagn. Pathol. 7, 149 (2012).

pubmed: 23111165 pmcid: 3500209 doi: 10.1186/1746-1596-7-149

Shirakawa, H. et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int. J. Oncol. 34, 649–656 (2009).

pubmed: 19212669

Lei, J. Y., Bourne, P. A., diSant’Agnese, P. A. & Huang, J. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver. Am. J. Clin. Pathol. 125, 519–525 (2006).

pubmed: 16627262 doi: 10.1309/59TNEFALUL5WJ94M

Zong, Y., Xiong, Y., Dresser, K., Yang, M. & Bledsoe, J. R. Polyclonal PAX8 expression in carcinomas of the biliary tract – frequent non-specific staining represents a potential diagnostic pitfall. Ann. Diagn. Pathol. 53, 151762 (2021).

pubmed: 34102541 doi: 10.1016/j.anndiagpath.2021.151762

Clark, B. Z., Beriwal, S., Dabbs, D. J. & Bhargava, R. Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas. Am. J. Clin. Pathol. 142, 64–71 (2014).

pubmed: 24926087 doi: 10.1309/AJCP8H2VBDSCIOBF

Zen, Y. et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod. Pathol. 20, 701–709 (2007).

pubmed: 17431410 doi: 10.1038/modpathol.3800788

Fujikura, K. et al. Comparative clinicopathological study of biliary intraductal papillary neoplasms and papillary cholangiocarcinomas. Histopathology 69, 950–961 (2016).

pubmed: 27410028 doi: 10.1111/his.13037

Komori, T. et al. CT imaging comparison between intraductal papillary neoplasms of the bile duct and papillary cholangiocarcinomas. Eur. Radiol. 29, 3132–3140 (2019).

pubmed: 30519930 doi: 10.1007/s00330-018-5841-0

Schlitter, A. M. et al. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways. Mod. Pathol. 27, 73–86 (2014).

pubmed: 23828315 doi: 10.1038/modpathol.2013.112

Goeppert, B. et al. Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma. Hepatology 69, 2091–2106 (2019).

pubmed: 30615206 doi: 10.1002/hep.30493

Quigley, B. et al. Hepatobiliary mucinous cystic neoplasms with ovarian type stroma (so-called “hepatobiliary cystadenoma/cystadenocarcinoma”): clinicopathologic analysis of 36 cases illustrates rarity of carcinomatous change. Am. J. Surg. Pathol. 42, 95–102 (2018).

pubmed: 29016404 doi: 10.1097/PAS.0000000000000963

Zen, Y. et al. Mucinous cystic neoplasms of the liver: a clinicopathological study and comparison with intraductal papillary neoplasms of the bile duct. Mod. Pathol. 24, 1079–1089 (2011).

pubmed: 21516077 doi: 10.1038/modpathol.2011.71

Chan-On, W. et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat. Genet. 45, 1474–1478 (2013).

pubmed: 24185513 doi: 10.1038/ng.2806

Farshidfar, F. et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 19, 2878–2880 (2017).

pubmed: 28658632 pmcid: 6141445 doi: 10.1016/j.celrep.2017.06.008

Fujimoto, A. et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat. Commun. 6, 6120 (2015).

pubmed: 25636086 doi: 10.1038/ncomms7120

Gao, Q. et al. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. Gastroenterology 146, 1397–1407 (2014).

pubmed: 24503127 doi: 10.1053/j.gastro.2014.01.062

Nepal, C. et al. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology 68, 949–963 (2018).

pubmed: 29278425 doi: 10.1002/hep.29764

Nakamura, H. et al. Genomic spectra of biliary tract cancer. Nat. Genet. 47, 1003–1010 (2015).

pubmed: 26258846 doi: 10.1038/ng.3375

Ong, C. K. et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat. Genet. 44, 690–693 (2012).

pubmed: 22561520 doi: 10.1038/ng.2273

Zou, S. et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat. Commun. 5, 5696 (2014).

pubmed: 25526346 doi: 10.1038/ncomms6696

Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).

pubmed: 23770567 pmcid: 3919509 doi: 10.1038/nature12213

Andersen, J. B. et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142, 1021–1031.e15 (2012).

pubmed: 22178589 doi: 10.1053/j.gastro.2011.12.005

Sia, D. et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144, 829–840 (2013).

pubmed: 23295441 doi: 10.1053/j.gastro.2013.01.001

Montal, R. et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J. Hepatol. 73, 315–327 (2020).

pubmed: 32173382 pmcid: 8418904 doi: 10.1016/j.jhep.2020.03.008

Marquardt, J. U., Andersen, J. B. & Thorgeirsson, S. S. Functional and genetic deconstruction of the cellular origin in liver cancer. Nat. Rev. Cancer 15, 653–667 (2015).

pubmed: 26493646 doi: 10.1038/nrc4017

Moeini, A., Haber, P. K. & Sia, D. Cell of origin in biliary tract cancers and clinical implications. JHEP Rep. 3, 100226 (2021).

pubmed: 33665585 pmcid: 7902553 doi: 10.1016/j.jhepr.2021.100226

Holczbauer, A. et al. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology 145, 221–231 (2013).

pubmed: 23523670 doi: 10.1053/j.gastro.2013.03.013

Guest, R. V. et al. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. Cancer Res. 74, 1005–1010 (2014).

pubmed: 24310400 doi: 10.1158/0008-5472.CAN-13-1911

Lee, J. S. et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat. Genet. 36, 1306–1311 (2004).

pubmed: 15565109 doi: 10.1038/ng1481

Lee, J. S. et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. 12, 410–416 (2006).

pubmed: 16532004 doi: 10.1038/nm1377

Massa, A. et al. Evolution of the experimental models of cholangiocarcinoma. Cancers 12, 2308 (2020).

pubmed: 32824407 pmcid: 7463907 doi: 10.3390/cancers12082308

Fava, G. et al. γ-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res. 65, 11437–11446 (2005).

pubmed: 16357152 doi: 10.1158/0008-5472.CAN-05-1470

Mohr, R. et al. In vivo models for cholangiocarcinoma–what can we learn for human disease? Int. J. Mol. Sci. 21, 4993 (2020).

pubmed: 32679791 pmcid: 7404171 doi: 10.3390/ijms21144993

Cadamuro, M. et al. Animal models of cholangiocarcinoma: what they teach us about the human disease. Clin. Res. Hepatol. Gastroenterol. 42, 403–415 (2018).

pubmed: 29753731 doi: 10.1016/j.clinre.2018.04.008

Hu, M. H. et al. Targeting SHP-1-STAT3 signaling: a promising therapeutic approach for the treatment of cholangiocarcinoma. Oncotarget 8, 65077–65089 (2017).

pubmed: 29029413 pmcid: 5630313 doi: 10.18632/oncotarget.17779

Samukawa, E. et al. Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest. Int. J. Oncol. 51, 1674–1684 (2017).

pubmed: 29075786 pmcid: 5673010 doi: 10.3892/ijo.2017.4177

Pawar, P. et al. Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clin. Cancer Res. 15, 1288–1296 (2009).

pubmed: 19228732 pmcid: 2905314 doi: 10.1158/1078-0432.CCR-08-1150

Colyn, L. et al. Dual targeting of G9a and DNA methyltransferase-1 for the treatment of experimental cholangiocarcinoma. Hepatology 73, 2380–2396 (2021).

pubmed: 33222246 doi: 10.1002/hep.31642

Hou, Y. J. et al. Inhibition of active autophagy induces apoptosis and increases chemosensitivity in cholangiocarcinoma. Lab. Invest. 91, 1146–1157 (2011).

pubmed: 21647092 doi: 10.1038/labinvest.2011.97

Merino-Azpitarte, M. et al. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. J. Hepatol. 67, 72–83 (2017).

pubmed: 28237397 pmcid: 5502751 doi: 10.1016/j.jhep.2017.02.017

Meng, F., Yamagiwa, Y., Ueno, Y. & Patel, T. Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J. Hepatol. 44, 1055–1065 (2006).

pubmed: 16469407 doi: 10.1016/j.jhep.2005.10.030

Lobe, C. et al. Zinc finger E-box binding homeobox 1 promotes cholangiocarcinoma progression through tumor dedifferentiation and tumor-stroma paracrine signaling. Hepatology 74, 3194–3212 (2021).

pubmed: 34297412 doi: 10.1002/hep.32069

Gentilini, A. et al. Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells. Hepatology 74, 2007–2020 (2021).

pubmed: 33959996 doi: 10.1002/hep.31888

Vallejo, A. et al. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. J. Hepatol. 75, 363–376 (2021).

pubmed: 33887357 doi: 10.1016/j.jhep.2021.03.028

Olaru, A. V. et al. MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology 54, 2089–2098 (2011).

pubmed: 21809359 doi: 10.1002/hep.24591

Zhang, J., Han, C. & Wu, T. MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin. Gastroenterology 143, 246–256.e8 (2012).

pubmed: 22484120 doi: 10.1053/j.gastro.2012.03.045

Zhu, H., Han, C., Lu, D. & Wu, T. miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator. Am. J. Pathol. 184, 2828–2839 (2014).

pubmed: 25239565 pmcid: 4188863 doi: 10.1016/j.ajpath.2014.06.024

Zhu, H. et al. Neuropilin-1 regulated by miR-320 contributes to the growth and metastasis of cholangiocarcinoma cells. Liver Int. 38, 125–135 (2018).

pubmed: 28618167 doi: 10.1111/liv.13495

Han, S. et al. Suppression of miR-16 promotes tumor growth and metastasis through reversely regulating YAP1 in human cholangiocarcinoma. Oncotarget 8, 56635–56650 (2017).

pubmed: 28915618 pmcid: 5593589 doi: 10.18632/oncotarget.17832

Razumilava, N. et al. Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma. J. Hepatol. 60, 599–605 (2014).

pubmed: 24239776 doi: 10.1016/j.jhep.2013.11.005

McVeigh, L. E. et al. Development of orthotopic tumour models using ultrasound-guided intrahepatic injection. Sci. Rep. 9, 9904 (2019).

pubmed: 31289364 pmcid: 6616610 doi: 10.1038/s41598-019-46410-6

Erice, O. et al. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1335–1344 (2018).

pubmed: 28916388 doi: 10.1016/j.bbadis.2017.08.016

Cardinale, V. et al. Profiles of cancer stem cell subpopulations in cholangiocarcinomas. Am. J. Pathol. 185, 1724–1739 (2015).

pubmed: 25892683 pmcid: 4450332 doi: 10.1016/j.ajpath.2015.02.010

Wu, Z. et al. Significance of S100P as a biomarker in diagnosis, prognosis and therapy of opisthorchiasis-associated cholangiocarcinoma. Int. J. Cancer 138, 396–408 (2016).

pubmed: 26312563 doi: 10.1002/ijc.29721

Cadamuro, M. et al. Low-dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma. Cancer Res. 76, 4775–4784 (2016).

pubmed: 27328733 pmcid: 4987167 doi: 10.1158/0008-5472.CAN-16-0188

Peraldo Neia, C. et al. Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line. Oncotarget 7, 86766–86780 (2016).

pubmed: 27902465 pmcid: 5349952 doi: 10.18632/oncotarget.13575

Peraldo-Neia, C. et al. Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. BMC Cancer 14, 918 (2014).

pubmed: 25479910 pmcid: 4289395 doi: 10.1186/1471-2407-14-918

Wang, Y. et al. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Cancer Lett. 380, 163–173 (2016).

pubmed: 27216979 pmcid: 5119950 doi: 10.1016/j.canlet.2016.05.017

Saha, S. K. et al. Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov. 6, 727–739 (2016).

pubmed: 27231123 pmcid: 5458737 doi: 10.1158/2159-8290.CD-15-1442

Kabashima, A. et al. Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma. J. Hepatol. 68, 1228–1238 (2018).

pubmed: 29408314 pmcid: 5960421 doi: 10.1016/j.jhep.2018.01.026

Lidsky, M. E. et al. Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies. NPJ Precis. Oncol. 6, 75 (2022).

pubmed: 36274097 pmcid: 9588766 doi: 10.1038/s41698-022-00320-5

Wu, Q. et al. EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 12, 1378–1395 (2022).

pubmed: 35420673 pmcid: 9064956 doi: 10.1158/2159-8290.CD-21-1168

Sirica, A. E. et al. A novel “patient-like” model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology 47, 1178–1190 (2008).

pubmed: 18081149 doi: 10.1002/hep.22088

Fingas, C. D. et al. A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology 52, 550–561 (2010).

pubmed: 20683954 doi: 10.1002/hep.23729

Blechacz, B. R. et al. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology 50, 1861–1870 (2009).

pubmed: 19821497 doi: 10.1002/hep.23214

Smoot, R. L. et al. A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res. 70, 1960–1969 (2010).

pubmed: 20160031 pmcid: 2831099 doi: 10.1158/0008-5472.CAN-09-3535

Fingas, C. D. et al. Targeting PDGFR-β in cholangiocarcinoma. Liver Int. 32, 400–409 (2012).

pubmed: 22133064

Mertens, J. C. et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 73, 897–907 (2013).

pubmed: 23221385 doi: 10.1158/0008-5472.CAN-12-2130

Yamada, D. et al. IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology 61, 1627–1642 (2015).

pubmed: 25580681 doi: 10.1002/hep.27687

Rizvi, S. et al. YAP-associated chromosomal instability and cholangiocarcinoma in mice. Oncotarget 9, 5892–5905 (2018).

pubmed: 29464042 doi: 10.18632/oncotarget.23638

Saborowski, A. et al. Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proc. Natl Acad. Sci. USA 110, 19513–19518 (2013).

pubmed: 24154728 pmcid: 3845141 doi: 10.1073/pnas.1311707110

Loeuillard, E. et al. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J. Clin. Invest. 130, 5380–5396 (2020).

pubmed: 32663198 pmcid: 7524481 doi: 10.1172/JCI137110

Fabris, L., Sato, K., Alpini, G. & Strazzabosco, M. The tumor microenvironment in cholangiocarcinoma progression. Hepatology 73 (Suppl. 1), 75–85 (2021).

pubmed: 32500550 doi: 10.1002/hep.31410

Fitzhugh, O. G. & Nelson, A. A. Liver tumors in rats fed thiourea or thioacetamide. Science 108, 626–628 (1948).

pubmed: 17783352 doi: 10.1126/science.108.2814.626

Al-Bader, A. et al. Cholangiocarcinoma and liver cirrhosis in relation to changes due to thioacetamide. Mol. Cell Biochem. 208, 1–10 (2000).

pubmed: 10939622 doi: 10.1023/A:1007082515548

Kamp, E. J. et al. Genetic alterations during the neoplastic cascade towards cholangiocarcinoma in primary sclerosing cholangitis. J. Pathol. 258, 227–235 (2022).

pubmed: 35897137 pmcid: 9825993 doi: 10.1002/path.5994

Yeh, C. N., Maitra, A., Lee, K. F., Jan, Y. Y. & Chen, M. F. Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis 25, 631–636 (2004).

pubmed: 14656942 doi: 10.1093/carcin/bgh037

Lozano, E. et al. Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. Mol. Cancer Res. 12, 91–100 (2014).

pubmed: 24255171 doi: 10.1158/1541-7786.MCR-13-0503

Verna, L., Whysner, J. & Williams, G. M. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol. Ther. 71, 57–81 (1996).

pubmed: 8910949 doi: 10.1016/0163-7258(96)00062-9

Yang, H. et al. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. Gastroenterology 141, 378–388.e4 (2011).

pubmed: 21440549 doi: 10.1053/j.gastro.2011.03.044

Thamavit, W. et al. Promotion of cholangiocarcinogenesis in the hamster liver by bile duct ligation after dimethylnitrosamine initiation. Carcinogenesis 14, 2415–2417 (1993).

pubmed: 8242874 doi: 10.1093/carcin/14.11.2415

Thamavit, W., Pairojkul, C., Tiwawech, D., Shirai, T. & Ito, N. Strong promoting effect of Opisthorchis viverrini infection on dimethylnitrosamine-initiated hamster liver. Cancer Lett. 78, 121–125 (1994).

pubmed: 8180954 doi: 10.1016/0304-3835(94)90040-X

Maronpot, R. R., Giles, H. D., Dykes, D. J. & Irwin, R. D. Furan-induced hepatic cholangiocarcinomas in Fischer 344 rats. Toxicol. Pathol. 19, 561–570 (1991).

pubmed: 1668599 doi: 10.1177/019262339101900401

Erice, O. et al. Genetic mouse models as in vivo tools for cholangiocarcinoma research. Cancers 11, 1868 (2019).

pubmed: 31769429 pmcid: 6966555 doi: 10.3390/cancers11121868

Xu, X. et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J. Clin. Invest. 116, 1843–1852 (2006).

pubmed: 16767220 pmcid: 1474816 doi: 10.1172/JCI27282

O’Dell, M. R. et al. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res. 72, 1557–1567 (2012).

pubmed: 22266220 pmcid: 3306549 doi: 10.1158/0008-5472.CAN-11-3596

Hill, M. A. et al. Kras and Tp53 mutations cause cholangiocyte- and hepatocyte-derived cholangiocarcinoma. Cancer Res. 78, 4445–4451 (2018).

pubmed: 29871934 pmcid: 6097629 doi: 10.1158/0008-5472.CAN-17-1123

Ikenoue, T. et al. A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. Sci. Rep. 6, 23899 (2016).

pubmed: 27032374 pmcid: 4817147 doi: 10.1038/srep23899

Lin, Y. K. et al. Combination of Kras activation and PTEN deletion contributes to murine hepatopancreatic ductal malignancy. Cancer Lett. 421, 161–169 (2018).

pubmed: 29452147 doi: 10.1016/j.canlet.2018.02.017

Saha, S. K. et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature 513, 110–114 (2014).

pubmed: 25043045 pmcid: 4499230 doi: 10.1038/nature13441

Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 465, 966 (2010).

pubmed: 20559394 pmcid: 3766976 doi: 10.1038/nature09132

Wu, M. J. et al. Mutant IDH inhibits IFNγ-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. Cancer Discov. 12, 812–835 (2022).

pubmed: 34848557 pmcid: 8904298 doi: 10.1158/2159-8290.CD-21-1077

Zender, S. et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell 23, 784–795 (2013).

pubmed: 23727022 doi: 10.1016/j.ccr.2013.04.019

Yuan, D. et al. Kupffer cell-derived TNF triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS. Cancer Cell 31, 771–789.e6 (2017).

pubmed: 28609656 pmcid: 7909318 doi: 10.1016/j.ccell.2017.05.006

Nakagawa, H. et al. Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands. Proc. Natl Acad. Sci. USA 114, E3806–E3815 (2017).

pubmed: 28439013 pmcid: 5441746 doi: 10.1073/pnas.1619416114

Guest, R. V. et al. Notch3 drives development and progression of cholangiocarcinoma. Proc. Natl Acad. Sci. USA 113, 12250–12255 (2016).

pubmed: 27791012 pmcid: 5086988 doi: 10.1073/pnas.1600067113

Farazi, P. A. et al. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 66, 6622–6627 (2006).

pubmed: 16818635 doi: 10.1158/0008-5472.CAN-05-4609

Younger, N. T. et al. In vivo modeling of patient genetic heterogeneity identifies new ways to target cholangiocarcinoma. Cancer Res. 82, 1548–1559 (2022).

pubmed: 35074757 pmcid: 9359731 doi: 10.1158/0008-5472.CAN-21-2556

Fan, B. et al. Cholangiocarcinomas can originate from hepatocytes in mice. J. Clin. Invest. 122, 2911–2915 (2012).

pubmed: 22797301 pmcid: 3408746 doi: 10.1172/JCI63212

Yamaguchi, N., Morioka, H., Ohkura, H., Hirohashi, S. & Kawai, K. Establishment and characterization of the human cholangiocarcinoma cell line HChol-Y1 in a serum-free, chemically defined medium. J. Natl Cancer Inst. 75, 29–35 (1985).

pubmed: 2989602

Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J. & Zhu, A. X. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 7, 943–962 (2017).

pubmed: 28818953 pmcid: 5586506 doi: 10.1158/2159-8290.CD-17-0245

Lau, D. K. et al. Genomic profiling of biliary tract cancer cell lines reveals molecular subtypes and actionable drug targets. iScience 21, 624–637 (2019).

pubmed: 31731200 pmcid: 6889747 doi: 10.1016/j.isci.2019.10.044

Scherer, D. et al. RNA sequencing of hepatobiliary cancer cell lines: data and applications to mutational and transcriptomic profiling. Cancers 12, 2510 (2020).

pubmed: 32899426 pmcid: 7565451 doi: 10.3390/cancers12092510

Ghandi, M. et al. Next-generation characterization of the cancer cell line encyclopedia. Nature 569, 503–508 (2019).

pubmed: 31068700 pmcid: 6697103 doi: 10.1038/s41586-019-1186-3

Nagtegaal, I. D. et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 76, 182–188 (2020).

pubmed: 31433515 doi: 10.1111/his.13975

Knuth, A. et al. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J. Hepatol. 1, 579–596 (1985).

pubmed: 4056357 doi: 10.1016/S0168-8278(85)80002-7

Fausther, M. et al. Establishment and characterization of rat portal myofibroblast cell lines. PLoS ONE 10, e0121161 (2015).

pubmed: 25822334 pmcid: 4378927 doi: 10.1371/journal.pone.0121161

Kaur, G. & Dufour, J. M. Cell lines: valuable tools or useless artifacts. Spermatogenesis 2, 1–5 (2012).

pubmed: 22553484 pmcid: 3341241 doi: 10.4161/spmg.19885

Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013).

pubmed: 23839242 doi: 10.1038/ncomms3126

Ertel, A., Verghese, A., Byers, S. W., Ochs, M. & Tozeren, A. Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Mol. Cancer 5, 55 (2006).

pubmed: 17081305 pmcid: 1635729 doi: 10.1186/1476-4598-5-55

Gillet, J. P. et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc. Natl Acad. Sci. USA 108, 18708–18713 (2011).

pubmed: 22068913 pmcid: 3219108 doi: 10.1073/pnas.1111840108

Chow, M. & Rubin, H. Clonal selection versus genetic instability as the driving force in neoplastic transformation. Cancer Res. 60, 6510–6518 (2000).

pubmed: 11103821

Massani, M. et al. Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: a novel in vitro model to study tumor-stroma interactions. Oncol. Rep. 30, 1143–1148 (2013).

pubmed: 23807641 doi: 10.3892/or.2013.2568

Fraveto, A. et al. Sensitivity of human intrahepatic cholangiocarcinoma subtypes to chemotherapeutics and molecular targeted agents: a study on primary cell cultures. PLoS ONE 10, e0142124 (2015).

pubmed: 26571380 pmcid: 4646673 doi: 10.1371/journal.pone.0142124

Carnevale, G. et al. Activation of Fas/FasL pathway and the role of c-FLIP in primary culture of human cholangiocarcinoma cells. Sci. Rep. 7, 14419 (2017).

pubmed: 29089545 pmcid: 5663931 doi: 10.1038/s41598-017-14838-3

Lustri, A. M. et al. TGF-β signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: a study on human primary cell cultures. PLoS ONE 12, e0183932 (2017).

pubmed: 28873435 pmcid: 5584931 doi: 10.1371/journal.pone.0183932

Ku, J. L. et al. Establishment and characterisation of six human biliary tract cancer cell lines. Br. J. Cancer 87, 187–193 (2002).

pubmed: 12107841 pmcid: 2376107 doi: 10.1038/sj.bjc.6600440

Pastor, D. M. et al. Primary cell lines: false representation or model system? A comparison of four human colorectal tumors and their coordinately established cell lines. Int. J. Clin. Exp. Med. 3, 69–83 (2010).

pubmed: 20369042 pmcid: 2848308

Vaquero, J. et al. The IGF2/IR/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to EGFR inhibition in cholangiocarcinoma. Clin. Cancer Res. 24, 4282–4296 (2018).

pubmed: 29716918 doi: 10.1158/1078-0432.CCR-17-3725

Zhou, Z. et al. Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3. J. Immunother. Cancer 9, e001946 (2021).

pubmed: 33692217 pmcid: 7949476 doi: 10.1136/jitc-2020-001946

Okabe, H. et al. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 16, 2555–2564 (2009).

pubmed: 19548033 doi: 10.1245/s10434-009-0568-4

Nicolas-Boluda, A. et al. Photothermal depletion of cancer-associated fibroblasts normalizes tumor stiffness in desmoplastic cholangiocarcinoma. ACS Nano 14, 5738–5753 (2020).

pubmed: 32338871 doi: 10.1021/acsnano.0c00417

Cadamuro, M. et al. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. J. Hepatol. 70, 700–709 (2019).

pubmed: 30553841 doi: 10.1016/j.jhep.2018.12.004

Li, L. et al. Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model. Hepatology 65, 501–514 (2017).

pubmed: 27474881 doi: 10.1002/hep.28735

Fennema, E., Rivron, N., Rouwkema, J., van Blitterswijk, C. & de Boer, J. Spheroid culture as a tool for creating 3D complex tissues. Trends Biotechnol. 31, 108–115 (2013).

pubmed: 23336996 doi: 10.1016/j.tibtech.2012.12.003

Sato, T. et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459, 262–265 (2009).

pubmed: 19329995 doi: 10.1038/nature07935

Huch, M., Boj, S. F. & Clevers, H. Lgr5(+) liver stem cells, hepatic organoids and regenerative medicine. Regen. Med. 8, 385–387 (2013).

pubmed: 23826690 doi: 10.2217/rme.13.39

Sato, K. et al. Organoids and spheroids as models for studying cholestatic liver injury and cholangiocarcinoma. Hepatology 74, 491–502 (2021).

pubmed: 33222247 doi: 10.1002/hep.31653

Girard, Y. K. et al. A 3D fibrous scaffold inducing tumoroids: a platform for anticancer drug development. PLoS ONE 8, e75345 (2013).

pubmed: 24146752 pmcid: 3797770 doi: 10.1371/journal.pone.0075345

Wu, F. et al. Generation of hepatobiliary organoids from human induced pluripotent stem cells. J. Hepatol. 70, 1145–1158 (2019).

pubmed: 30630011 doi: 10.1016/j.jhep.2018.12.028

Soroka, C. J., Assis, D. N. & Boyer, J. L. Patient-derived organoids from human bile: an in vitro method to study cholangiopathies. Methods Mol. Biol. 1981, 363–372 (2019).

pubmed: 31016667 doi: 10.1007/978-1-4939-9420-5_24

Roos, F. J. M. et al. Human bile contains cholangiocyte organoid-initiating cells which expand as functional cholangiocytes in non-canonical Wnt stimulating conditions. Front. Cell Dev. Biol. 8, 630492 (2020).

pubmed: 33634107 doi: 10.3389/fcell.2020.630492

Lampis, A. et al. MIR21 drives resistance to heat shock protein 90 inhibition in cholangiocarcinoma. Gastroenterology 154, 1066–1079.e5 (2018).

pubmed: 29113809 doi: 10.1053/j.gastro.2017.10.043

Li, L. et al. Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity. JCI Insight 4, e121490 (2019).

pubmed: 30674722 pmcid: 6413833 doi: 10.1172/jci.insight.121490

Broutier, L. et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat. Protoc. 11, 1724–1743 (2016).

pubmed: 27560176 doi: 10.1038/nprot.2016.097

Artegiani, B. et al. Probing the tumor suppressor function of BAP1 in CRISPR-engineered human liver organoids. Cell Stem Cell 24, 927–943.e6 (2019).

pubmed: 31130514 doi: 10.1016/j.stem.2019.04.017

Sun, L. et al. Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes. Nat. Cell Biol. 21, 1015–1026 (2019).

pubmed: 31332348 doi: 10.1038/s41556-019-0359-5

Cristinziano, G. et al. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. J. Hepatol. 75, 351–362 (2021).

pubmed: 33741397 doi: 10.1016/j.jhep.2021.02.032

Leyva-Illades, D., McMillin, M., Quinn, M. & Demorrow, S. Cholangiocarcinoma pathogenesis: role of the tumor microenvironment. Transl. Gastrointest. Cancer 1, 71–80 (2012).

pubmed: 23002431 pmcid: 3448449

Hogdall, D., Lewinska, M. & Andersen, J. B. Desmoplastic tumor microenvironment and immunotherapy in cholangiocarcinoma. Trends Cancer 4, 239–255 (2018).

pubmed: 29506673 doi: 10.1016/j.trecan.2018.01.007

Cadamuro, M. et al. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1435–1443 (2018).

pubmed: 28757170 doi: 10.1016/j.bbadis.2017.07.028

Mertens, J. C., Rizvi, S. & Gores, G. J. Targeting cholangiocarcinoma. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1454–1460 (2018).

pubmed: 28844952 doi: 10.1016/j.bbadis.2017.08.027

Tanimizu, N. et al. Generation of functional liver organoids on combining hepatocytes and cholangiocytes with hepatobiliary connections ex vivo. Nat. Commun. 12, 3390 (2021).

pubmed: 34099675 pmcid: 8185093 doi: 10.1038/s41467-021-23575-1

Lee, H. et al. Cell-printed 3D liver-on-a-chip possessing a liver microenvironment and biliary system. Biofabrication 11, 025001 (2019).

pubmed: 30566930 doi: 10.1088/1758-5090/aaf9fa

Allan, A. et al. Patient-specific 3D printed model of biliary ducts with congenital cyst. Quant. Imaging Med. Surg. 9, 86–93 (2019).

pubmed: 30788249 pmcid: 6351815 doi: 10.21037/qims.2018.12.01

Kendre, G. et al. The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion-driven cholangiocarcinoma. Hepatology 74, 1357–1370 (2021).

pubmed: 33709535 doi: 10.1002/hep.31799

Wintachai, P. et al. Diagnostic and prognostic value of circulating cell-free DNA for cholangiocarcinoma. Diagnostics 11, 999 (2021).

pubmed: 34070951 pmcid: 8228499 doi: 10.3390/diagnostics11060999

Csoma, S. L. et al. Circulating cell-free DNA-based comprehensive molecular analysis of biliary tract cancers using next-generation sequencing. Cancers 14, 233 (2022).

pubmed: 35008396 pmcid: 8750273 doi: 10.3390/cancers14010233

Varghese, A. M. et al. Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations. JCO Precis Oncol. 5, 44–50 (2021).

doi: 10.1200/PO.20.00178

Goyal, L. et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 9, 1064–1079 (2019).

pubmed: 31109923 pmcid: 6677584 doi: 10.1158/2159-8290.CD-19-0182

van Tienderen, G. S. et al. Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions. Cancer Cell 40, 226–230 (2022).

pubmed: 35148815 doi: 10.1016/j.ccell.2022.02.001

Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273–286 (2019).

pubmed: 29394327 doi: 10.1093/biostatistics/kxx069

Lozano, E. et al. Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT). J. Control. Release 216, 93–102 (2015).

pubmed: 26278512 doi: 10.1016/j.jconrel.2015.08.022

Katz, S. F. et al. Disruption of Trp53 in livers of mice induces formation of carcinomas with bilineal differentiation. Gastroenterology 142, 1229–1239.e3 (2012).

pubmed: 22342966 doi: 10.1053/j.gastro.2012.02.009

Tschaharganeh, D. F. et al. p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell 158, 579–592 (2014).

pubmed: 25083869 pmcid: 4221237 doi: 10.1016/j.cell.2014.05.051

El Khatib, M. et al. Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo. PLoS ONE 8, e77433 (2013).

pubmed: 24204826 pmcid: 3813685 doi: 10.1371/journal.pone.0077433

Ikenoue, T. et al. Establishment and analysis of a novel mouse line carrying a conditional knockin allele of a cancer-specific FBXW7 mutation. Sci. Rep. 8, 2021 (2018).

pubmed: 29386660 pmcid: 5792591 doi: 10.1038/s41598-018-19769-1

Manieri, E. et al. JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma. Proc. Natl Acad. Sci. USA 117, 16492–16499 (2020).

pubmed: 32601222 pmcid: 7368313 doi: 10.1073/pnas.2002672117

Cubero, F. J. et al. Loss of c-Jun N-terminal kinase 1 and 2 function in liver epithelial cells triggers biliary hyperproliferation resembling cholangiocarcinoma. Hepatol. Commun. 4, 834–851 (2020).

pubmed: 32490320 pmcid: 7262317 doi: 10.1002/hep4.1495

Marsh, V., Davies, E. J., Williams, G. T. & Clarke, A. R. PTEN loss and KRAS activation cooperate in murine biliary tract malignancies. J. Pathol. 230, 165–173 (2013).

pubmed: 23483557 doi: 10.1002/path.4189

Falcomata, C. et al. Genetic screens identify a context-specific PI3K/p27(Kip1) node driving extrahepatic biliary cancer. Cancer Discov. 11, 3158–3177 (2021).

pubmed: 34282029 pmcid: 7612573 doi: 10.1158/2159-8290.CD-21-0209

Sekiya, S. & Suzuki, A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J. Clin. Invest. 122, 3914–3918 (2012).

pubmed: 23023701 pmcid: 3484442 doi: 10.1172/JCI63065

Crawford, D. R. et al. Characterization of liver injury, oval cell proliferation and cholangiocarcinogenesis in glutathione S-transferase A3 knockout mice. Carcinogenesis 38, 717–727 (2017).

pubmed: 28535182 pmcid: 5862260 doi: 10.1093/carcin/bgx048